2025 Q4 -tulosraportti
Vain PDF
137 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. | 1 päivä |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·4 t sittenImpossible 100kr Circio unfortunately why 500000 people must buy share100kr?🤷🏾🤷🏾🤷🏾
Are you completely stuck Why should it be impossible for 500.000 people to buy the Circio share for 100 kr., when 500.000 people buy the NVIDIA share at a much higher price than it cost 5 years ago?
·8 t sittenHappy weekend everyone. I have a small question regarding acquisition. If there is an acquisition in the long term, and we get, say, 100 kr per share. Will it then just be 100 kr per share? Or does the compound interest effect also come on top of that again, like when returns increase?
I note that there's a lot of talk about acquisitions, there are several possibilities for realizing value for Circio. A licensing agreement is probably the most immediate in the first instance.
·8 t sittenCircio – what are they actually building? I have reviewed Circios messages, presentations, and reports from 2025–2026. What becomes clear is that circVec is no longer just being tested as one technology in one type of gene therapy. The company is building a platform where circVec is combined with various delivery systems, vectors, and modalities. This does not mean that all collaborations will succeed. Several are early research. But the breadth is interesting. circVec Circio is developing a DNA vector platform that produces circular RNA inside the cell. The goal is higher and more long-lasting protein expression. Reported: up to 40x higher AAV expression in heart (circVec 3.2/4.0) and up to 50x in eye. Expression alone is not enough – the technology must also be delivered to the correct tissue and cell. Therefore, the delivery collaborations are central. Erik has previously indicated that further optimizations could lead to a new generation (circVec 5.0). IP strengthening is also important – new patent applications strengthen the position for future licensing or acquisition discussions. Key collaborations Top-5 pharma (CNS) – Fully funded feasibility from Nov 2025. Progressed to in vivo. The strongest external validation case. Acuitas – T-cell-targeted LNP + circVec for in vivo CAR-T. GenAssist – Tissue-specific AAV capsids (muscle/T-cells). AaviGen – Heart-targeted AAV capsids. Tcelltech – nanoSMAR + circVec for in vivo CAR-T/TCR-T. United Immunity – CAR-M. Full Circles (Aug 2026) – Immune-silent C4DNA + circVec. Avenue – Optimization of protein secretion. The pattern AAV (CNS, heart, muscle, eye) + LNP/non-viral (T-cells, CAR-T, CAR-M) + high/durable expression. Circio is building an expression platform that can be linked to others' delivery – a model that opens for licensing. The company has also previously signaled that they may consider bringing in or acquiring complementary delivery technology if the right opportunity arises. The 20 % emission authorization gives them flexibility to act quickly. Lubor has mentioned that there is no planned use of the authorization. Capital and organization Approx. 620 MNOK raised in H1 2026. Runway until at least 2030. The board has been strengthened with Dr. Dinah Sah (formerly CSO Voyager / VP Research Alnylam) and Robert Burns. Sah has experience taking RNA and AAV programs towards the clinic. Calendar Aug 31: Half-year report Sep 1: R&D-webcast (new data heart, CNS, in vivo CAR-T) Sep 2: Pareto Healthcare Conference Sep 10–11: RNA World 2026 Sep 23–25: LSX RNA Leaders USA Oct 5–7: Cell & Gene Meeting on the Mesa Oct 27–30: ESGCT Hamburg (oral presentation on circVec for T-cell therapies) Nov 9–11: BioEurope Nov 15: Cell & Gene Live London (Erik Wiklund speaker) Lubor Gaal has strongly recommended by e-mail to participate in the webcast on September 1, and said that the company will present new data and a comprehensive update on R&D, business development, and finance. This is a clear positive signal. What is most important? 1. CNS data from top-5 2. In vivo CAR-T progress 3. Heart 4. Potential new circVec generation / IP 5. Delivery solutions Realistic price ranges (approx. 13,20 NOK) - Weak/unclear data: 10–13 - Good data: 15–20 - Strong platform validation: 20–25+ Interpretation It is too early to say that Circio has a complete expression + delivery platform. But the direction is clear. They are testing circVec broadly, have capital, are strengthening IP and the board, and are preparing for the clinic. The most important thing in the coming days is whether more programs show the same effect: higher and more long-lasting expression combined with delivery that provides therapeutic benefit. If that happens, the market may have to re-evaluate what Circio is. But be sober: Preclinical data is not clinic, and research collaborations are not licensing agreements. Therefore, September 1 will be especially interesting.
- 11 t sitten"Circio has now entered its next phase of development, aiming to bring a lead therapeutic candidate forward to clinical entry in 2029" https://www.circio.com/en/circio-holding-asa-minutes-from-the-extraordinary-general-meeting-25-august-2026/
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
137 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·4 t sittenImpossible 100kr Circio unfortunately why 500000 people must buy share100kr?🤷🏾🤷🏾🤷🏾Are you completely stuck Why should it be impossible for 500.000 people to buy the Circio share for 100 kr., when 500.000 people buy the NVIDIA share at a much higher price than it cost 5 years ago?
- ·8 t sittenHappy weekend everyone. I have a small question regarding acquisition. If there is an acquisition in the long term, and we get, say, 100 kr per share. Will it then just be 100 kr per share? Or does the compound interest effect also come on top of that again, like when returns increase?I note that there's a lot of talk about acquisitions, there are several possibilities for realizing value for Circio. A licensing agreement is probably the most immediate in the first instance.
- ·8 t sittenCircio – what are they actually building? I have reviewed Circios messages, presentations, and reports from 2025–2026. What becomes clear is that circVec is no longer just being tested as one technology in one type of gene therapy. The company is building a platform where circVec is combined with various delivery systems, vectors, and modalities. This does not mean that all collaborations will succeed. Several are early research. But the breadth is interesting. circVec Circio is developing a DNA vector platform that produces circular RNA inside the cell. The goal is higher and more long-lasting protein expression. Reported: up to 40x higher AAV expression in heart (circVec 3.2/4.0) and up to 50x in eye. Expression alone is not enough – the technology must also be delivered to the correct tissue and cell. Therefore, the delivery collaborations are central. Erik has previously indicated that further optimizations could lead to a new generation (circVec 5.0). IP strengthening is also important – new patent applications strengthen the position for future licensing or acquisition discussions. Key collaborations Top-5 pharma (CNS) – Fully funded feasibility from Nov 2025. Progressed to in vivo. The strongest external validation case. Acuitas – T-cell-targeted LNP + circVec for in vivo CAR-T. GenAssist – Tissue-specific AAV capsids (muscle/T-cells). AaviGen – Heart-targeted AAV capsids. Tcelltech – nanoSMAR + circVec for in vivo CAR-T/TCR-T. United Immunity – CAR-M. Full Circles (Aug 2026) – Immune-silent C4DNA + circVec. Avenue – Optimization of protein secretion. The pattern AAV (CNS, heart, muscle, eye) + LNP/non-viral (T-cells, CAR-T, CAR-M) + high/durable expression. Circio is building an expression platform that can be linked to others' delivery – a model that opens for licensing. The company has also previously signaled that they may consider bringing in or acquiring complementary delivery technology if the right opportunity arises. The 20 % emission authorization gives them flexibility to act quickly. Lubor has mentioned that there is no planned use of the authorization. Capital and organization Approx. 620 MNOK raised in H1 2026. Runway until at least 2030. The board has been strengthened with Dr. Dinah Sah (formerly CSO Voyager / VP Research Alnylam) and Robert Burns. Sah has experience taking RNA and AAV programs towards the clinic. Calendar Aug 31: Half-year report Sep 1: R&D-webcast (new data heart, CNS, in vivo CAR-T) Sep 2: Pareto Healthcare Conference Sep 10–11: RNA World 2026 Sep 23–25: LSX RNA Leaders USA Oct 5–7: Cell & Gene Meeting on the Mesa Oct 27–30: ESGCT Hamburg (oral presentation on circVec for T-cell therapies) Nov 9–11: BioEurope Nov 15: Cell & Gene Live London (Erik Wiklund speaker) Lubor Gaal has strongly recommended by e-mail to participate in the webcast on September 1, and said that the company will present new data and a comprehensive update on R&D, business development, and finance. This is a clear positive signal. What is most important? 1. CNS data from top-5 2. In vivo CAR-T progress 3. Heart 4. Potential new circVec generation / IP 5. Delivery solutions Realistic price ranges (approx. 13,20 NOK) - Weak/unclear data: 10–13 - Good data: 15–20 - Strong platform validation: 20–25+ Interpretation It is too early to say that Circio has a complete expression + delivery platform. But the direction is clear. They are testing circVec broadly, have capital, are strengthening IP and the board, and are preparing for the clinic. The most important thing in the coming days is whether more programs show the same effect: higher and more long-lasting expression combined with delivery that provides therapeutic benefit. If that happens, the market may have to re-evaluate what Circio is. But be sober: Preclinical data is not clinic, and research collaborations are not licensing agreements. Therefore, September 1 will be especially interesting.
- 11 t sitten"Circio has now entered its next phase of development, aiming to bring a lead therapeutic candidate forward to clinical entry in 2029" https://www.circio.com/en/circio-holding-asa-minutes-from-the-extraordinary-general-meeting-25-august-2026/
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. | 1 päivä |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
137 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. | 1 päivä |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·4 t sittenImpossible 100kr Circio unfortunately why 500000 people must buy share100kr?🤷🏾🤷🏾🤷🏾Are you completely stuck Why should it be impossible for 500.000 people to buy the Circio share for 100 kr., when 500.000 people buy the NVIDIA share at a much higher price than it cost 5 years ago?
- ·8 t sittenHappy weekend everyone. I have a small question regarding acquisition. If there is an acquisition in the long term, and we get, say, 100 kr per share. Will it then just be 100 kr per share? Or does the compound interest effect also come on top of that again, like when returns increase?I note that there's a lot of talk about acquisitions, there are several possibilities for realizing value for Circio. A licensing agreement is probably the most immediate in the first instance.
- ·8 t sittenCircio – what are they actually building? I have reviewed Circios messages, presentations, and reports from 2025–2026. What becomes clear is that circVec is no longer just being tested as one technology in one type of gene therapy. The company is building a platform where circVec is combined with various delivery systems, vectors, and modalities. This does not mean that all collaborations will succeed. Several are early research. But the breadth is interesting. circVec Circio is developing a DNA vector platform that produces circular RNA inside the cell. The goal is higher and more long-lasting protein expression. Reported: up to 40x higher AAV expression in heart (circVec 3.2/4.0) and up to 50x in eye. Expression alone is not enough – the technology must also be delivered to the correct tissue and cell. Therefore, the delivery collaborations are central. Erik has previously indicated that further optimizations could lead to a new generation (circVec 5.0). IP strengthening is also important – new patent applications strengthen the position for future licensing or acquisition discussions. Key collaborations Top-5 pharma (CNS) – Fully funded feasibility from Nov 2025. Progressed to in vivo. The strongest external validation case. Acuitas – T-cell-targeted LNP + circVec for in vivo CAR-T. GenAssist – Tissue-specific AAV capsids (muscle/T-cells). AaviGen – Heart-targeted AAV capsids. Tcelltech – nanoSMAR + circVec for in vivo CAR-T/TCR-T. United Immunity – CAR-M. Full Circles (Aug 2026) – Immune-silent C4DNA + circVec. Avenue – Optimization of protein secretion. The pattern AAV (CNS, heart, muscle, eye) + LNP/non-viral (T-cells, CAR-T, CAR-M) + high/durable expression. Circio is building an expression platform that can be linked to others' delivery – a model that opens for licensing. The company has also previously signaled that they may consider bringing in or acquiring complementary delivery technology if the right opportunity arises. The 20 % emission authorization gives them flexibility to act quickly. Lubor has mentioned that there is no planned use of the authorization. Capital and organization Approx. 620 MNOK raised in H1 2026. Runway until at least 2030. The board has been strengthened with Dr. Dinah Sah (formerly CSO Voyager / VP Research Alnylam) and Robert Burns. Sah has experience taking RNA and AAV programs towards the clinic. Calendar Aug 31: Half-year report Sep 1: R&D-webcast (new data heart, CNS, in vivo CAR-T) Sep 2: Pareto Healthcare Conference Sep 10–11: RNA World 2026 Sep 23–25: LSX RNA Leaders USA Oct 5–7: Cell & Gene Meeting on the Mesa Oct 27–30: ESGCT Hamburg (oral presentation on circVec for T-cell therapies) Nov 9–11: BioEurope Nov 15: Cell & Gene Live London (Erik Wiklund speaker) Lubor Gaal has strongly recommended by e-mail to participate in the webcast on September 1, and said that the company will present new data and a comprehensive update on R&D, business development, and finance. This is a clear positive signal. What is most important? 1. CNS data from top-5 2. In vivo CAR-T progress 3. Heart 4. Potential new circVec generation / IP 5. Delivery solutions Realistic price ranges (approx. 13,20 NOK) - Weak/unclear data: 10–13 - Good data: 15–20 - Strong platform validation: 20–25+ Interpretation It is too early to say that Circio has a complete expression + delivery platform. But the direction is clear. They are testing circVec broadly, have capital, are strengthening IP and the board, and are preparing for the clinic. The most important thing in the coming days is whether more programs show the same effect: higher and more long-lasting expression combined with delivery that provides therapeutic benefit. If that happens, the market may have to re-evaluate what Circio is. But be sober: Preclinical data is not clinic, and research collaborations are not licensing agreements. Therefore, September 1 will be especially interesting.
- 11 t sitten"Circio has now entered its next phase of development, aiming to bring a lead therapeutic candidate forward to clinical entry in 2029" https://www.circio.com/en/circio-holding-asa-minutes-from-the-extraordinary-general-meeting-25-august-2026/
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt